Abstract
Background
Dipstick urine tests are used for general health screening in Japan, but how the test results (e.g., glucosuria) relate to mortality is unknown.
Methods
Subjects participated in a nationwide screening in 2008 in six districts in Japan. We identified those who might have died using the national database of death certificates from 2008 to 2012 (total registered ~ 6 million) and verified candidates with the regional National Health Insurance Agency and public health nurses. Diabetes mellitus (DM) was defined as HbA1c ≥ 6.5%, fasting blood glucose ≥ 126 mg/dl, or medicated for DM. Hazard ratio (HR) and 95% confidence interval (CI) were calculated by Cox proportional hazard analysis. Glucosuria was defined as dipstick ≥ 1 +.
Results
Among 209,060 subjects, we identified 2714 fatalities (median follow-up 3.57 years). Crude mortality rates were 1.2% for those without glucosuria and 3.4% for those with glucosuria. After adjusting for sex, age, body mass index, comorbidity (DM, hypertension, and dyslipidemia), history (stroke, heart disease, and kidney disease), and lifestyle (smoking, drinking, walking, and exercise), the HR (95% CI) for dipstick glucosuria was 1.475 (1.166–1.849, P < 0.001). DM subjects with glucosuria (N = 4655) had a higher HR [1.302 (1.044–1.613, P = 0.020)] than DM subjects without glucosuria (N = 20,245), and non-DM subjects with glucosuria (N = 470) had a higher HR [2.511 (1.539–3.833, P < 0.001)] than non-DM subjects without glucosuria (N = 183,690).
Conclusion
Dipstick glucosuria significantly affected mortality in Japanese community-based screening participants.
Similar content being viewed by others
References
Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on eGFR and dipstick proteinuria: analysis of the participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244–9.
Iseki K, Asahi K, Yamagata K, et al. Mortality risk among screened subjects of the Specific Health Check and Guidance Program in Japan 2008–2012. Clin Exp Nephrol. 2017. https://doi.org/10.1007/s10157-017-1392-y. (Epub ahead of print).
Iseki K, Konta T, Asahi K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the Specific Health Check and Guidance Program in Japan. Nephrol Dial Transpl. 2017. https://doi.org/10.1093/ndt/gfx213. (Epub ahead of print).
Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;59:852–5.
Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transpl. 2012;27:4273–87.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11–26.
Hung CC, Lin HYH, Lee JJ, et al. Glycosuria and renal outcomes in patients with nondiabetic advanced chronic kidney disease. Sci Rep. 2016;6:39372.
Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):S62–S69.
Sato Y, Yano Y, Fujimoto S, et al. Glycohemoglobin not as predictive as fasting glucose as a measure of prediabetes in predicting proteinuria. Nephrol Dial Transpl. 2012;27(10):3862–8.
Lal RA, Maahs DM. Clinical use of continuous glucose monitoring in pediatrics. Diabetes Technol Ther. 2017;19(S2):S37–S43.
Kovatchev BP. Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425–36.
Andersson DK, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabetes Med. 1993;10:167–73.
Kondo M, Yamagata K, Hoshi SL, et al. Budget impact analysis of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2014;18(6):885 – 91.
Nagai M, Murakami Y, Tamakoshi A, et al. Fasting but not casual blood glucose is associated with pancreatic cancer mortality in Japanese: EPOCH-JAPAN. Cancer Causes Control. 2017;28(6):625–33.
Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;90:1175–83.
Wang JY, Yang JH, Xu J, et al. Renal tubular damage may contribute more to acute hyperglycemia induced kidney injury in non-diabetic conscious rats. J Diabetes Complicat. 2015;29:621–8.
Slyne J, Slattery C, McMorrow T, et al. New developments concerning the proximal tubule in diabetic nephropathy: in vitro models and mechanisms. Nephrol Dial Transpl. 2015;30(Suppl 4):iv60–i67.
Nordquist L, Friederich-Persson M, Fasching A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26:328 – 38.
Tang SC, Yiu WH, Lin M, et al. Diabetic nephropathy and proximal tubular damage. J Ren Nutr. 2015;25:230–3.
Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. https://doi.org/10.1056/NEJMoa1611925. (Epub ahead of print).
Wanner C. EMPA-REG outcome: the nephrologist’s point of view. Am J Cardiol. 2017;120(suppl):S59-S67.
Wakisaka M, Nagao T. Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. Glycobiology. 2017. https://doi.org/10.1093/glycob/cwx047. (Epub ahead of print).
Selph S, Dana T, Blazina I, et al. Screening for type 2 diabetes mellitus: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2015;162:765–76.
Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–6.
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Matb. 2016;23:1060–5.
Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–9.
Kocogullari CU, Kunt AT, Aksoy R, et al. Hemoglobin A1c predicts acute kidney injury after coronary artery bypass surgery in non-diabetic patients. Braz J Cardiovasc Surg. 2017;32(2):83 – 9.
Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91(6):1300–11.
Yokoyama H, Kanno S, Takahashi S, et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol. 2009;4:1432–40.
Furuichi K, Yuzawa Y, Shimizu M, et al. Nationwide multicenter kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transpl. 2017. https://doi.org/10.1093/ndt/gfw417. (Epub ahead of print).
Usui T, Kanda E, Iseki C, et al. Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population. Nephrology. 2017. https://doi.org/10.1111/nep.13093. (Epub ahead of print).
Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014;18:613–20.
Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. PLoS One. 2016;11(3):e0151422.
Sekikawa A, Tominaga M, Takahashi K, et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care. 1993;16(4):570–4.
Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920–4.
de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17:2120–6.
Acknowledgements
This study was not possible without the generous support of the public health nurses, the Kokuho Agency in each district. This work was supported by a Health and Labor Sciences Research Grants for “Study on the design of the comprehensive health care system for chronic kidney disease (CKD) based on the individual risk assessment by Specific Health Checkup” from the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-Aid for “Research on Advanced Chronic Kidney Disease (REACH-J), Practical Research Project for Renal Disease” from the Japan Agency for Medical Research and Development, AMED.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
All authors have declared that no conflict of interest exists.
Ethics approval
All procedures performed in studies involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (Fukushima Medical University; IRB Approval Number #1485, #2771) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
This study was performed according to Ethical Guidelines for Medical and Health Research Involving Human Subjects enacted by MHLW of Japan [http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000069410.pdf and http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf]. In the context of the guideline, the investigators shall not necessarily be required to obtain informed consent, but we made public information concerning this study on the web [http://www.fmu.ac.jp/univ/sangaku/data/koukai_2/2771.pdf] and ensured the opportunities for the research subjects to refuse use of their personal information.
About this article
Cite this article
Iseki, K., Konta, T., Asahi, K. et al. Glucosuria and all-cause mortality among general screening participants. Clin Exp Nephrol 22, 850–859 (2018). https://doi.org/10.1007/s10157-017-1528-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-017-1528-0